Asked aboutthe process to sales, MV stated that IMM has no intention of marketing productsthemselves. “Pharma companies are our customers”. Its’ not news, but I’d neverheard him put it so unequivocally before. In conversation later, he reiteratedthe process is to sell each product IP to the pharma on the basis ofmilestones, success and royalty. Same for anything new going forward.
Kbear, again thanks mate......That clears a lot of my thinking......
Immutep the collaborator, has possible retail links with it's partners, which if trial outcomes
are positive you would expect the respective partners would be the buyer.....
OK that's the possibilities of our collaborations........SO...
Where does that leave AIPAC?......If trials are successful does it go to the open market and we
retain "EFTI" for different research in matters other than breast cancer?
Notes from the AGM, page-5
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.020(7.02%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.0¢ | 29.0¢ | $1.171M | 3.900M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 101067 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 8068 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
